Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study
Xiaoyue Du(Inner Mongolia Agricultural University), Bo Shen(Jiangsu Cancer Hospital), Wei Zhu(Jiangsu Cancer Hospital), Run Shi(Jiangsu Province Hospital), Shaodi Wen(Jiangsu Cancer Hospital), Ruotong Wang(Jiangsu Cancer Hospital), Xin Wang(Nanjing Medical University), Yihan Zhang(Tianjin University of Technology), Jifeng Feng(Zhejiang Cancer Hospital), Xiaoliu Wu(Jiangsu Cancer Hospital), Jingwei Xia(Jiangsu Cancer Hospital), Banzhou Pan(Nanjing General Hospital of Nanjing Military Command)
Cited by 16
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
|Experimental and Molecular Pathology|2005|388
Mesenchymal Stern Cells from Adult Human Bone Marrow Differentiate into a Cardiomyocyte Phenotype In Vitro
|Experimental Biology and Medicine|2004|372